<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211010052719N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-26</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of the effects of three conservative treatment methods on temporomandibular disorders</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the effects of three conservative treatment methods on temporomandibular disorders</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59463</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were randomly allocated to 3 treatment groups. A central randomization unit was contacted by phone to ensure allocation concealment and assign the enrolled patient to each treatment group. The central randomization unit had prepared a list of numbers from 1 to 30 that were allocated randomly to 3 equal groups using a website (https://www.random.org.) which generated a list of random numbers in 3 columns. Before randomization, the first column was considered the Stabilization splint treatment group, the second column the low level laser treatment group, and the third column the combination treatment group (low level laser + Stabilization splint).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Temporomandibular disorders.</hc_freetext>
      <i_freetext>Intervention 1: Stabilization splint treatment group: Splints are made according to Okeson's instructions and necessary adjustments are made. The patient is instructed to use the splint for 12 hours a day for three months. The outcomes are evaluated at intervals before splint treatment, one month, three months, after the start of treatment. Intervention 2: Low level Laser treatment group: A diode laser device, noncontact mode, continuous wave, 0.1 W (100 mW), 810 nm, 6 J / cm, 2,60 s / session are used, which is performed in three sessions per week for three weeks ( A total of nine sessions). The laser is applied to the origin, insertion, and body areas of the masseter muscle and the anterior, middle, and posterior parts of the temporalis muscle , as well as to the center of the upper joint space, about one cm in front of the tragus. The outcomes are evaluated at intervals before splint treatment, one month, three months, after the start of treatment. Intervention 3: Combination treatment group: This group of treatments is initially treated with low level laser according to the mentioned protocol. Then, immediately after the end of the laser treatment, they are treated with a splint according to the protocol for three months. The outcomes are evaluated at intervals before splint treatment, one month, three months, after the start of treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Data will be analyzed and presented in the final report of the results such as articles as tables and figures.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Afshari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshjoo Blvd, Velenjak, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19839-63113</zip>
        <telephone>+98 31 5366 4431</telephone>
        <email>afsharyzhr1@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Afshari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshjoo Blvd, Velenjak, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19839-63113</zip>
        <telephone>+98 31 5366 4431</telephone>
        <email>afsharyzhr1@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Chronic orofacial pain (more than three months) with or without restriction in opening the mouth.
Diagnosis of Temporomandibular disorder (Axis I)  based on the RDC / TMD diagnostic criteria.
History of no previous treatment for TMD during the last month.
Having natural dentition</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Recent fracture of mandibular bone.
History of recent facial trauma
Congenital / developmental disorders of the jaw.
Systemic musculoskeletal disease.
Fibromyalgia.
Previous or current history of the cancer.
Skin lesions at the laser site.
Pregnancy.
Diagnosis of Temporomandibular disorder of articular origin based on the RDC / TMD diagnostic criteria.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M26.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Temporomandibular joint disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Stabilization splint treatment group: Splints are made according to Okeson's instructions and necessary adjustments are made. The patient is instructed to use the splint for 12 hours a day for three months. The outcomes are evaluated at intervals before splint treatment, one month, three months, after the start of treatment.</i_keyword>
      <i_keyword>Low level Laser treatment group: A diode laser device, noncontact mode, continuous wave, 0.1 W (100 mW), 810 nm, 6 J / cm, 2,60 s / session are used, which is performed in three sessions per week for three weeks ( A total of nine sessions). The laser is applied to the origin, insertion, and body areas of the masseter muscle and the anterior, middle, and posterior parts of the temporalis muscle , as well as to the center of the upper joint space, about one cm in front of the tragus. The outcomes are evaluated at intervals before splint treatment, one month, three months, after the start of treatment.</i_keyword>
      <i_keyword>Combination treatment group: This group of treatments is initially treated with low level laser according to the mentioned protocol. Then, immediately after the end of the laser treatment, they are treated with a splint according to the protocol for three months. The outcomes are evaluated at intervals before splint treatment, one month, three months, after the start of treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: Before treatment, immediately after treatment, one month and three months after the end of treatment. Method of measurement: visual scale analogue (VAS).</prim_outcome>
      <prim_outcome>Maximum mouth opening with NO assistance. Timepoint: Before treatment, immediately after treatment, one month and three months after the end of treatment. Method of measurement: By ruler in millimeters.</prim_outcome>
      <prim_outcome>Right &amp; left and anterior lateral movement of mandible. Timepoint: Before treatment, immediately after treatment, one month and three months after the end of treatment. Method of measurement: By ruler in millimeters.</prim_outcome>
      <prim_outcome>Functional limitations of jaw. Timepoint: Before treatment, immediately after treatment, one month and three months after the end of treatment. Method of measurement: visual scale analogue (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-09</approval_date>
        <contact_name>the Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Daneshjoo Blvd, Velenjak, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
